Compare AbCellera Biologics Inc (ABCL) vs Hilton Hotels Corporation Common Stock (HLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Hilton Hotels Corporation Common Stock — how do they compare? AbCellera Biologics Inc trades at $9.06 (market cap $2.85B), while Hilton Hotels Corporation Common Stock trades at $319 (market cap $70.00B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 24.6× AbCellera Biologics Inc's market cap, and Hilton Hotels Corporation Common Stock pays a 0.19% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | HLT | |
|---|---|---|
Market Cap | $2.85B | $70.00B |
Sector | Health | Consumer Cyclical |
52-Week High | $9.76 | $350.22 |
52-Week Low | $2.78 | $256.75 |
Enterprise Value | $2.45B | $83.01B |
Dividend Yield | — | 0.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.
The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.
Hilton Worldwide (HLT) trades at $317.60, down 1.36% with bearish technical signals. The stock shows strong fundamentals with consistent earnings beats and revenue growth from $12.04B in 2025 to projected $12.5B in 2026. Analyst consensus remains positive with 57% buy ratings and a $352.88 price target, though technical indicators show selling pressure near key resistance at $321.
HLT offers growth potential from travel recovery and pipeline expansion but faces risks from premium valuation (P/E 46.64), rising debt levels (debt-to-asset ratio increased to 73.88% in 2025), and labor disputes. The stock's near-term performance depends on Q3 earnings meeting expectations of $2.38 EPS and managing global demand volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →
